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Abstract
Background: Recent studies have identified thousands of sense-antisense gene pairs across different genomes by
computational mapping of cDNA sequences. These studies have shown that approximately 25% of all
transcriptional units in the human and mouse genomes are involved in cis-sense-antisense pairs. However, the
number of known sense-antisense pairs remains limited because currently available cDNA sequences represent
only a fraction of the total number of transcripts comprising the transcriptome of each cell type.
Methods: To discover novel antisense transcripts encoded in the antisense strand of important genes, such as
cancer-related genes, we conducted expression analyses of antisense transcripts using our custom microarray
platform along with 2376 probes designed specifically to detect the potential antisense transcripts of 501 well-
known genes suitable for cancer research.
Results: Using colon cancer tissue and normal tissue surrounding the cancer tissue obtained from 6 patients, we
found that antisense transcripts without poly(A) tails are expressed from approximately 80% of these well-known
genes. This observation is consistent with our previous finding that many antisense transcripts expressed in a cell
are poly(A)-. We also identified 101 and 71 antisense probes displaying a high level of expression specifically in
normal and cancer tissues respectively.
Conclusion: Our microarray analysis identified novel antisense transcripts with expression profiles specific to cancer
tissue, some of which might play a role in the regulatory networks underlying oncogenesis and thus are potential
targets for further experimental validation. Our microarray data are available at http://www.brc.riken.go.jp/
ncrna2007/viewer-Saito-01/index.html.
Background
Non-coding RNAs are one class of RNAs that do not
encode proteins but have specific cellular activities.
Some non-coding RNAs are antisense RNAs encoded
on the antisense strand of protein-coding genes. Recent
progress in sequencing technologies has allowed the
rapid sequence analysis of the large amount of RNAs
that are transcribed in the cell. For example, the large-
scale cDNA sequencing projects conducted by the
FANTOM consortium revealed that a large proportion
of the mouse genome is transcribed into RNAs and that
many of these RNAs do not have protein-coding poten-
tial and thus are considered non-coding RNAs [1,2].
Studies using tiling arrays further support these observa-
tions and have revealed the presence of RNA-encoding
regions in the genome by computational mapping [3].
Computational mapping has revealed that many RNAs
are located on the antisense strand of the protein-coding
genes in the same genomic region; approximately 25%
of transcriptional units are involved in cis-sense-anti-
sense gene pairs in the human and mouse genomes,
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experimentally determined functions of antisense RNAs
are limited, some have been shown to regulate tran-
scription from the sense strand [6]. Thus, expressional
analyses of sense-antisense transcripts may shed light on
the mechanisms underlying the control of these
transcripts.
In our previous studies [7,10], we conducted compre-
hensive expressional analyses of sense-antisense tran-
scripts in human and mouse cells. In these studies large
amounts of transcripts were detected by the random
priming method, but not by the oligo-dT priming
method, thus suggesting that these transcripts are poly
(A)- and not reflected by cDNA sequences, which rely
on the existence of poly(A) tails. Comprehensive cluster
analysis of the expression ratio of sense and antisense
transcripts is a powerful approach to characterize
expression patterns of sense-antisense transcripts in var-
ious tissues. We found that expression balances of some
of these transcripts were altered in specific tissues.
Furthermore, Northern hybridization analysis of several
selected sense-antisense transcripts showed smeary
hybridization patterns in the mouse, thus indicating that
the transcribed region in the genome may vary and that
the cDNA sequences do not always reflect the actual
sizes of the transcripts. Therefore, the design of micro-
array probes based on cDNA sequences obtained by
large-scale cDNA sequencing projects is not appropriate
for the detection of all transcripts comprising the
transcriptome.
Subsequently, we designed microarray probes referred
to as artificial antisense sequence (AFAS) probes specific
for sequences in the antisense strand of known tran-
scription units originating from the sense strand. In this
way, we were able to detect the expression of novel anti-
sense RNAs, which were not detected by using cDNA
sequences [11]. These AFAS probes were spotted onto
microarray slides and used in our microarray platform
to generate expression data for the analysis of antisense
transcripts. Using mouse adult tissues, we previously
found that 66.1% of 635 genes targeted for such expres-
sional analysis showed positive expression from the anti-
sense strand, suggesting that our AFAS probes can
efficiently detect novel antisense transcripts [11].
We then chose mouse cancer tissues for expressional
analyses of sense-antisense transcripts, because most
oncogenesis is caused by abnormalities in gene
sequences or in the regulatory systems controlling gene
expression, and possibly also by unknown RNAs tran-
scribed from the antisense strand. Uncovering how gene
expression is regulated in cancer cells may lead us to a
better understanding of the mechanisms and signaling
networks underlying oncogenesis and metastasis [12].
Several early studies succeeded in identifying genes
expressed specifically in cancer cells; however, most stu-
dies have focused on investigating the expression of
messenger RNAs, which encode proteins [13-17].
Several studies have identified non-coding RNAs
expressed specifically in cancer cells [18,19]; however,
those focused on antisense RNAs are limited [20,21].
Using AFAS probes, we found that expression of anti-
sense transcripts from 95 well-annotated genes showed
altered expression level in cancer tissues [11]. Some of
their expressions were validated using RT-PCR, North-
ern blot analysis, and in situ hybridization, thus suggest-
ing that our platform can efficiently detect novel
antisense transcripts, some of which may be regulated in
cancer cells.
Here, using the same microarray platform, we analyzed
expression patterns of antisense transcripts in human tis-
sue. First we characterized the expression patterns of
sense-antisense transcripts, based on available cDNA
sequences, in colon (colorectal) cancer tissues and in
normal tissues surrounding the cancer tissues. Although
expression balances (ratios) of most of sense and anti-
sense transcript pairs did not change between patients or
between normal and cancer tissues, we found 68 sense-
antisense transcripts whose expression balances were
altered specifically in colon cancer tissues. Then, to iden-
tify novel antisense RNAs expressed in cancer tissues, we
used the AFAS probes to analyze the expression patterns
of sequences in the antisense strand of well-known pro-
tein-coding genes that are suitable for cancer research as
defined in the Atlas Human Cancer 1.2 Array. Sixty-mer
probes were designed for every 500 bps of the antisense
strand of protein-coding genes. We used the oligo-dT
and random priming methods for transcript generation
in order to screen both the poly(A)+ and poly(A)- tran-
script populations in total RNA extracted from colon
cancer samples obtained from 6 patients.
Using random priming, we detected gene expression
with approximately 40% of the AFAS probes, which cor-
respond to approximately 80% of the well-known genes.
Among them, 172 probes detected twofold differences in
expression levels of antisense transcripts between cancer
tissue and normal tissue, demonstrating the usefulness of
our approach to discover novel antisense transcripts,
some of which might be related to the regulation of gene
expression in cancer cells. Although we used only colon
cancer tissues in this study, we believe that our approach
is applicable to other types of cancer tissues.
Results
The expression balance of 68 cDNA-based sense-
antisense transcripts is altered in colon cancer tissues
We previously established a custom microarray platform
(designated as 11 k) to analyze the expression patterns
of sense-antisense transcripts in human and mouse
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on the basis of available cDNA sequences as [10]. For
validation of this microarray platform, three sense-anti-
sense pairs were selected for Northern and in situ hybri-
dization analyses to confirm their transcription [7,10].
Here, we conducted DNA microarray analyses by using
the same set of probes designed for 2621 sense-anti-
sense pairs in [10] to detect transcripts expressed in
colon cancer tissues. These probes comprise 2358 pairs
for the detection of protein-coding transcripts only, 250
pairs for the detection of protein-coding transcripts
paired with non-protein-coding transcripts, and 13 pairs
for the detection of non-protein-coding transcripts only.
Protein-coding transcripts, as defined in our previous
study [10], are those giving a significant hit to known
protein sequences by BLASTX searches (homology
search from DNA to protein). Otherwise, we defined the
transcripts as non-coding. Total RNAs were extracted
from colon cancer tissue and normal tissue surrounding
the cancer tissue obtained from 6 patients. Fluorescence
labeling of transcripts was performed by using both
oligo-dT and random priming methods.
Microarray data analysis revealed that the expression
ratios between sense and antisense transcripts were clus-
tered, as shown in our previous studies (Additional file
1: Figure S1) [7,10]. Although most of the expression
ratios between sense and antisense transcripts did not
change between patients or between normal and cancer
tissues, we found sense-antisense transcripts showing
altered expression balances in colon cancer tissues. For
example, Figure 1 (also listed in Additional file 2: Table
S1) shows that the expression balances of 68 sense-anti-
sense transcript pairs were reversed in cancer tissues.
For 29 pairs among them, the sense transcripts showed
a >10% increase in expression levels in cancer tissues,
whereas the corresponding antisense transcripts showed
a similar decrease in at least three of six patients
(according to expression data obtained by random prim-
ing). For the remaining 39 pairs, the expression levels of
the sense transcripts was >10% greater in normal tissues
than in cancer tissues, whereas the corresponding anti-
sense transcripts showed a similar level of increased
expression in cancer tissues. We analyzed functional
annotations (GO, Gene Ontology [22]) of genes corre-
sponding to these sense-antisense pairs. The cellular
processes in which these genes are involved were biased
toward signal transduction, cell adhesion, and cell differ-
entiation, which play important roles in oncogenesis and
metastasis (Additional file 2: Table S2). The up-regula-
tion and down-regulation of sense-antisense transcripts
can be more precisely assessed by analysis of the expres-
sion ratios between sense and antisense transcripts in
normal and cancer tissues (Additional file 1: Figure S2).
In this analysis, we identified six sense-antisense gene
pairs in which the sense gene was protein-coding and
the antisense gene was non-coding, as defined pre-
viously [10]. Interestingly, two of the sense genes were
involved in cell differentiation, which may be related to
cancer. Subsequently, we screened for novel non-coding
transcripts that might be encoded by the antisense
strand. Our previous work showed that vast amounts of
transcripts were poly(A)- [7,10] and thus they may not
be detected by a cDNA-based approach. Therefore, we
screened for these novel transcripts by using the AFAS
(a)
(b)
Sense / Antisense = 3
Sense / Antisense = 1/3
Sense / Antisense = 1
Protein-coding
- Protein-coding
Protein-coding
- Non-coding
Protein-coding
- Protein-coding
Protein-coding
- Non-coding
Normal Cancer
Normal Cancer
Figure 1 Clustering analysis of the expression ratio of the
sense and antisense pair of transcripts showing altered
expression balances. Only the clustering result obtained by the
random priming approach is shown. The green color indicates
higher expression (threefold or more) of the sense transcript
compared with its antisense counterpart. The red color indicates
lower expression of the sense transcript (1/3-fold or less) compared
with its antisense counterpart. (a) Clustering result for sense-
antisense pairs where the sense gene is up-regulated and the
corresponding antisense gene is down-regulated in cancer tissues.
(b) Clustering result for sense-antisense pairs where the sense gene
is down-regulated and the corresponding antisense gene is up-
regulated in cancer tissues.
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random priming approach.
AFAS transcripts are expressed from about 80% of the
well-known genes and most are poly(A)-
Our established microarray platform (custom microarray
platform 11 k) comprises 501 probes covering well-known
genes suitable for cancer research, including oncogenes
and tumor suppressors. We obtained expression data for
cancer tissue obtained from 6 patients and validated these
data by comparison with previously obtained data, as
described in the methods section. Our microarray plat-
form also contains 2376 AFAS probes designed to corre-
spond to every 500 bases of the antisense strand of exonic
regions of well-known genes suitable for cancer research
to screen for transcripts originating from the antisense
strand. These genomic regions, genes encoded in these
regions, and transcripts originating from these regions,
were designated as AFAS regions, AFAS genes, and AFAS
transcripts, respectively. The AFAS probes detected fewer
transcripts than the probes corresponding to protein cod-
ing genes on the sense strand. Although most of the AFAS
regions were not transcribed, or were expressed only at
low levels, the detection of transcripts by the AFAS probes
implies the existence of antisense genes (Figure 2). For
example, for normal and cancer tissue, 14.8% and 8.3% of
AFAS probes, respectively, detected expression intensities
satisfying a conservative threshold (≥100)[11], according to
expression data obtained by oligo-dT priming. As
expected, the sense probes detected markedly more tran-
scripts, with 64.1% and 64.2% of the sense probes detect-
ing expression intensities in normal and cancer tissues,
respectively, that satisfy the same threshold. By compari-
son, more transcripts were detected with AFAS probes by
using the random priming approach to prepare target
cDNAs; approximately 39.4% and 38.2% of the AFAS
probes satisfied the conservative threshold (≥100) in nor-
mal and cancer tissues, respectively, by using random
priming (P = 7.19×10
-1061, c
2 test). The rates of probes
detecting positive expression according to more moderate
criteria provided by Agilent’s platform are summarized in
Additional file 2: Table S3. Figure 2 shows the higher over-
all expression levels detected by AFAS probes using ran-
dom priming compared with oligo dT priming in both
normal and cancer tissues. Since oligo-dT priming is
expected to label mRNAs, including unspliced pre-
mRNAs having poly(A) tails, whereas random priming is
expected to label all RNAs in a cell, these results indicate
that most of the transcripts originating from the AFAS
regions (AFAS transcripts) are poly(A)-. This finding is
consistent with the results of a previous study showing
that the majority of sense-antisense transcripts are poly
(A)- [7]. The possibility that these poly(A)- transcripts are
localized in the nucleus must be confirmed by biological
experiments. It is noteworthy that publicly available cDNA
sequences originating from the antisense strand can be
found for only 139 (27.7%) of the 501 well-known genes
used in the present study. This calculation is based on the
set of cDNA sequences used in our previous work [11].
Approximately 70% of the AFAS probes that detected
gene expression did not correspond to these cDNA
sequences. Thus, we suggest that these probes correspond
to potentially novel antisense RNAs. At least one AFAS
probe showed a median expression level (≥100), using ran-
dom priming, for 78.2% and 77.4% of the well-known
genes in normal and cancer tissues, respectively. Although
cross-hybridization of AFAS probes with transcripts must
be considered, our results reveal that our microarray plat-
form utilizing the AFAS probes and the random priming
method to prepare transcripts has the capacity to detect
novel transcripts from the antisense strand. Therefore, for
subsequent analyses, we focused on the expression data
using random priming to investigate the possible regula-
tory functions of identified poly(A)- RNAs.
The expressional level of 172 transcripts identified with
the AFAS probes is altered in colon cancer tissue
Transcripts identified by AFAS probes with altered
e x p r e s s i o nl e v e l si nc a n c e rt i s s u em i g h tp l a yar o l ei n
oncogenesis. Therefore, we first calculated the ratio of
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Figure 2 Distributions of microarray signal intensities obtained
using sense (top) and AFAS probes (bottom). Signals obtained
by the oligo-dT priming or by the random priming approach are
indicated. The graphs on the left represent the expression
distributions in normal tissues, whereas those on the right represent
the expression distributions in cancer tissues.
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and cancer tissues (cancer to normal ratio) for each
sense and AFAS transcript (Additional file 1: Figure S3).
We found many putative antisense genes (AFAS genes,
detected by the AFAS probes) with altered expression in
cancer tissues compared with normal tissue. We identi-
fied 71 AFAS transcripts expressed more than twofold
higher in colon cancer tissues than in normal tissues
and 101 AFAS transcripts expressed in colon cancer tis-
sues at a level less than 50% of the level found in nor-
mal tissue. These numbers were much greater than the
expected number of transcripts, which was identified as
50.14 ± 6.13 S.D by the random shuffling test.
We chose three AFAS probes that showed alterations
in expression level in cancer tissue by microarray analy-
sis and conducted RT-PCR to verify these results. Our
RT-PCR results (Figure 3) showed that for all three anti-
sense probes there were notable changes in expression
level between cancer tissues and normal tissues.
We also analyzed how the expression level of sense
transcript changes in response to the expressional
changes of antisense transcripts detected by AFAS
probes. When the oligo-dT priming method was used to
prepare the transcripts, the number of sense-AFAS pairs
that showed a concerted increase or decrease in expres-
sion level in cancer and normal tissues was 1451, which
is statistically higher than the expected number of
1260.19 (P =2 . 0 × 1 0
-20, c
2 test). This finding is consis-
tent with the results of a previous study showing a posi-
tive correlation between the expression of sense and
antisense transcripts [4,20]. However, no such positive
correlation was observed for expression data obtained
by random priming.
The cancer to normal ratio for the sense and antisense
transcript in each pair can be used to detect sense-
antisense transcript pairs having correlated or anti-cor-
related expression, as shown in Additional file 1: Figure
S3 for random priming. For example, there are 21
sense-AFAS pairs where expression of the sense tran-
script is increased twofold or more while the expression
of the AFAS transcript is decreased by 50% or more in
cancer tissues (plots in the lower right of the fourth
quadrant of Additional file 1: Figure S3).
T h es e n s et oa n t i s e n s er a t i oi sap o w e r f u lm e a s u r et o
characterize the expression balance of the sense and anti-
sense genes in particular genomic regions as demonstrated
by our previous studies [7,10]. To obtain a global picture
of changes in such expression balances for the sense-
AFAS pairs, we conducted clustering analyses. In particu-
lar, for data obtained by random priming we calculated
the sense to AFAS expression ratio for each sense-AFAS
pair and conducted hierarchical clustering (Additional file
1: Figure S4). By aligning the clustering results, we then
compared the expression balance patterns for data
obtained by oligo-dT priming with those obtained by ran-
dom priming for each sense-antisense pair.
Most of the AFAS probes revealed lower expression
levels than did the sense probes in both cancer tissue and
normal tissue, especially for the expression data obtained
by oligo-dT priming. However, by using the random
priming approach we detected 306 sense-AFAS pairs for
which the AFAS probes detected expression levels three
times (according to the median expression level among
the patients) those detected by the corresponding sense
probes, in both cancer tissue and normal tissue. In con-
trast, only 91 sense-AFAS pairs were detected by the
same criteria using oligo-dT priming (P =1 . 8 1 × 1 0
-29, c
2
test). This observation mostly corresponds to the red
region in the upper part of the heat map designated as
“random” in Additional file 1: Figure S4.
We then observed sense-AFAS probe pairs having
altered expression balances among normal and cancer
tissues; for example there were 44 sense-AFAS probe
pairs for which the sense transcript showed higher
expression than AFAS transcript in cancer tissues but
the balance was reversed in normal tissues for at least
three of the six patients (Figure 4a and Table 1). We
noted that for these 44 sense-AFAS pairs, there were at
least 10% differences in expression levels detected by
sense and AFAS probes, and both sense and AFAS
probes showed at least a 10% change in expression level
between normal and cancer tissues, for these three
patients. The observed number, 44, was much higher
than the expected number 12.07 ± 3.11 SD (Random
shuffling test). If the threshold of 10% was changed to
20% or 30%, the observed number of pairs decreased to
35 and 21, respectively, although the rate of biologically
relevant pairs within these pairs might increase. We also
screened for sense-AFAS probe pairs for which the
㻜
㻞
㻠
㻢
㻤
㻝㻜
㻝㻞
㻯㼤㼏㼘㻝㻞㻙㻭㻿 㻮㻾㻯㻭㻞㻙㻭㻿 㼀㻼㻡㻟㻮㻼㻞㻙㻭㻿
㻾
㼑
㼘
㼍
㼠
㼕
㼢
㼑
㻌
㻽
㼡
㼍
㼚
㼠
㼕
㼠
㼥
㻺㼛㼞㼙㼍㼘
㻯㼍㼚㼏㼑㼞
Figure 3 Expression levels of three AFAS transcripts in normal
and cancer tissues measured by RT-PCR. Sense gene symbols
followed by “-AS” are shown on the horizontal axis. The error bars
reflect the standard deviation of the technical duplicates.
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Page 5 of 15sense transcript showed lower expression than the AFAS
transcripts in cancer tissues but for which the balance
was reversed in normal tissues. We obtained five pairs
consistent with this scenario (Figure 4b and Table 1).
We also identified sense-AFAS transcript pairs for
which the sense transcript showed higher (lower)
expression than that of the AFAS gene, in cancer tis-
sues, where expression levels were based on expression
data from oligo-dT priming for sense transcripts and
random priming for AFAS transcripts (Additional file 2:
Table S4ab). This procedure might be rationalized by
the better detection of protein-coding gene expression
by using the oligo-dT priming approach and, conversely,
the better detection of RNA expression by the random
priming approach. Although transcripts detected by
oligo-dT priming and those detected by random priming
(a)
(b)
Normal Cancer Normal Cancer
Normal Cancer Normal Cancer
Oligo-dT Random
Sense / AFAS = 3
Sense / AFAS = 1/3
Sense / AFAS = 1
Oligo-dT Random
Figure 4 Clustering analysis of the expression ratio of well-known genes (sense transcripts) and their corresponding AFAS transcripts
showing altered expression balances. Clustering analysis was conducted for expression ratios obtained by the random priming approach.
Expression ratios obtained by the oligo-dT priming approach were aligned to the clustering results of the random priming approach. The green
color indicates higher expression detected by the sense probe compared with the corresponding AFAS probe (3-fold of more). The red color
indicates lower expression detected by the sense probe compared with its antisense counterpart (1/3-fold of less). Sense-AFAS probe pairs in the
figure correspond to those listed in Table 1. (a) Clustering result for sense-AFAS pairs where the sense gene is up-regulated and the
corresponding AFAS gene is down-regulated in cancer tissues. (b) Clustering result for sense-AFAS pairs where sense gene is down-regulated
and the corresponding antisense gene is up-regulated in cancer tissues.
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Page 6 of 15Table 1 List of sense-AFAS probe pairs detecting altered expression balances in normal tissue and cancer tissue in
patients with colon cancer based on the random priming approach
AFAS ID Diff. (%) Annotation
X07876-03 97.2 wingless-type MMTV integration site family member 2
L31951-03 94.1 mitogen-activated protein kinase 9
U29343-04 74.6 hyaluronan-mediated motility receptor (RHAMM)
U09304-01 63.3 ephrin-B1
U43746-02 62.6 breast cancer 2, early onset
X63629-03 57.8 cadherin 3, type 1, P-cadherin (placental)
M25753-01 54.5 cyclin B1
U69611-04 50.7 a disintegrin and metalloproteinase domain 17 (tumor necrosis factor, alpha, converting enzyme)
M63167-01 47.9 v-akt murine thymoma viral oncogene homolog 1
M77830-02 43.9 desmoplakin (DPI, DPII)
M29366-04 40.9 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
M15990-01 39.3 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1
X53586-04 38.4 integrin, alpha 6
U43746-15 37.1 breast cancer 2, early onset
J04088-07 36.5 topoisomerase (DNA) II alpha (170 kD)
X87852-02 36.5 plexin A3
X05232-03 32.7 matrix metalloproteinase 3 (stromelysin 1, progelatinase)
M29039-02 32.7 jun B proto-oncogene
X80343-01 32.4 cyclin-dependent kinase 5, regulatory subunit 1 (p35)
L34058-01 30.3 cadherin 13, H-cadherin (heart)
Y10479-01 30.3 E2F transcription factor 3
M14505-02 29.7 cyclin-dependent kinase 4
J02958-06 29.7 met proto-oncogene (hepatocyte growth factor receptor)
U43746-11 29.1 breast cancer 2, early onset
U58334-01 29.1 tumor protein p53 binding protein, 2
X63629-01 28.5 cadherin 3, type 1, P-cadherin (placental)
U58334-02 28.2 tumor protein p53 binding protein, 2
X56654-01 27.9 desmoglein 1
M81934-01 27.6 cell division cycle 25B
X66363-03 27.6 PCTAIRE protein kinase 1
M26880-04 26.8 ubiquitin C
U37139-02 25.6 integrin beta 3 binding protein (beta3-endonexin)
L29222-02 24.2 CDC-like kinase 1
U01038-02 21.9 polo-like kinase (Drosophila)
M35410-02 21.1 insulin-like growth factor binding protein 2 (36 kD)
M35296-07 18.9 v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene)
AF022385-02 18.6 programmed cell death 10
M30704-01 17.5 amphiregulin (schwannoma-derived growth factor)
U43142-01 16.1 vascular endothelial growth factor C
M32315-05 15.9 tumor necrosis factor receptor superfamily, member 1B
M85289-12 15.9 heparan sulfate proteoglycan 2 (perlecan)
AB000220-03 13.5 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C
U29343-01 11.2 hyaluronan-mediated motility receptor (RHAMM)
NM_005417-02 10.7 v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)
U16752-04 70.2 stromal cell-derived factor 1
D21337-07 35.2 collagen, type IV, alpha 6
Y00815-03 16.9 protein tyrosine phosphatase, receptor type, F
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they might be associated at the level of gene expression.
The sense-AFAS probe pairs listed in Table 1 are also
indicated in Additional file 1: Figure S3 (designated as
Sense up, AFAS down, corresponding to the first 44
pairs in Table 1 and Sense down, AFAS up, correspond-
ing to the last five pairs in Table 1).
The biological relevance of sense-AFAS genes can be
inferred from their expression patterns
To obtain a global view of the functions of the genes
corresponding to the sense-AFAS transcript pairs show-
ing altered expression balances among normal and can-
cer cells (shown in Table 1 and Additional file 2: Table
S4), we classified the known functions of the sense
genes on the basis of the annotations given in the Atlas
Human Cancer 1.2 Array (Additional file 2: Table S5).
Approximately 30% of the sense genes showing altered
expression balances with their corresponding AFAS
genes were oncogenes, tumor suppressor genes, or
genes related to cell cycle function. This finding demon-
strates that the design of our AFAS probes had the
capacity to efficiently detect transcripts originating from
the antisense strand of genes related to oncogenesis.
We generated bar graphs for the sense-AFAS pairs
shown in Table 1 and displayed the clearest cases in
F i g u r e s5a n d6 .O n eo ft h ee x a m p l e si st h es e n s e -
AFAS transcript pair detected with the sense probe for
mitogen-activated protein kinase 9 (MAPK9) and the
corresponding AFAS probe, L31951-03 (Figure 5). In
this case, the overall expression level of the sense gene
was higher in cancer tissues than in normal tissues,
and vice versa for the AFAS gene, based on the gen-
eration of target cDNAs with the random priming
approach. Four patients (No. 2, 12, 13, and 15) showed
clear expression balance alterations of the sense-AFAS
transcripts. The oligo-dT priming approach tended to
give higher expression levels of the sense genes than
did the random priming approach, presumably because
of the higher efficiency of oligo-dT priming for label-
ing transcripts with poly(A) tails. However, the random
priming approach was more efficient than the oligo-dT
priming approach in allowing the detection of the
putative antisense transcripts (AFAS transcripts) as
well as the detection of the changes in expression level
of these transcripts in normal tissue and cancer tissues.
Furthermore, the expression patterns of AFAS tran-
s c r i p t sw e r em o r el i k e l yt ob ed i f f e r e n tw i t ht h et w o
priming approaches (average correlation coefficient =
0.143) than those of the sense genes (average correla-
tion coefficient = 0.358, P =2 . 2 × 1 0
-16,M a n n - W h i t n e y
test). This result suggests that the sets of transcripts
originating from the AFAS regions might differ
depending on the priming method and that random
priming is the more efficient approach for detecting
these transcripts.
In some cases, multiple AFAS probes simultaneously
detected altered expression balances of specific sense-
AFAS transcripts. For example, three AFAS probes
designed to detect the transcripts encoded in the anti-
sense strand of BRCA2 (breast cancer 2, early onset,
U43746) revealed altered expression balances for the
sense-AFAS transcripts originating from this gene
(Table 1). This result suggests that for BRCA2, multiple
transcriptional units are under the same regulatory con-
trol or, alternatively, that a single long transcription unit
arises from the antisense strand. On the other hand, the
expression levels detected by some AFAS probes were
limited to a specific region of a gene. For example, of
the five AFAS probes designed to detect the transcripts
encoded in the antisense strand of cancer-related gene
ADAM metallopeptidase domain 17 (ADAM17,
U69611) only U69611-04 revealed an altered expression
balance with the sense transcript (Additional file 1: Fig-
ure S5). In this case, it is possible that the AFAS probe
maps to the transcriptional unit arising from the limited
region of the antisense strand. We have preliminary
results suggesting that transcripts detected by AFAS
probes are more likely to be situated at the 5’ end of the
corresponding sense genes (Additional file 1: Figure S6),
a result that we also reported in our previous study [11].
Discussion
In the present study we screened for novel antisense
transcripts using our previously established microarray
platform with AFAS probes and identified those
expressed at different levels in cancer tissues and nor-
mal tissues (Table 2). Although many studies have
Table 1 List of sense-AFAS probe pairs detecting altered expression balances in normal tissue and cancer tissue in
patients with colon cancer based on the random priming approach (Continued)
X04571-05 13.8 epidermal growth factor (beta-urogastrone)
L12002-06 10.9 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)
Identification (ID) of only the AFAS probes is shown. The format of the ID is: NCBI accession number of sense gene-serial number given to the AFAS probes, starting
from the 5’ end of the antisense region. Thus, the ID for the corresponding sense gene can be inferred from the AFAS probe ID. The column “Diff.” denotes the
minimum percentage of the differences in expression intensities between normal tissue, cancer tissue, and those obtained by using sense probes, and AFAS probes.
Only the third greatest value among six values for each patient is shown. The first 44 rows show the list of sense-AFAS probe pairs detecting up-regulated expression of
the sense transcript and down-regulated expression of the AFAS transcript in cancer tissues. The last five rows show the list of sense-AFAS probe pairs detecting down-
regulated expression of the sense gene and up-regulated expression of the AFAS gene in cancer tissues. These two lists are separated by a line.
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Page 8 of 15focused on investigating the expression of sense genes
with poly(A) tails in cancer tissue, very few studies at a
genome-wide level have investigated antisense genes
with no poly(A) tail. Our previous [7,10,11] and present
studies suggest that such antisense genes are transcribed
from many of the sense genes and should be included
in a thorough investigation of the gene regulatory net-
works underlying oncogenesis.
Hierarchical clustering of expression ratio of sense and
antisense genes followed by heat map creation is a
powerful approach to characterize genomic regions from
the view point of expression balances among the two
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Figure 5 Two examples of microarray expression levels for sense-AFAS probe pairs where the sense gene is up-regulated and its
AFAS gene is down-regulated.
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Page 9 of 15U43746-02: breast cancer 2, early onset
U29343-04: hyaluronan-mediated
motility receptor (RHAMM)
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Figure 6 Examples of microarray expression levels for sense-AFAS probe pairs detecting altered expression balances. U43746-02,
U29343-04 and U58334-02 are examples of cases where the sense gene is up-regulated and its AFAS gene is down-regulated in colon cancer
tissues. U16752-04 on the lower right is an example with the opposite tendency where the sense gene is down-regulated and its AFAS gene is
up-regulated in colon cancer tissues.
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Page 10 of 15strands; it shows genomic regions where either sense or
antisense strand is highly expressed compared to the
other strand. We expected that for most of the genomic
regions, sense genes are highly expressed compared to
antisense genes especially because sense genes are well-
known whereas most of their antisense counterparts are
unknown. This was the case for expression data
obtained by oligo-dT priming, but not for those
obtained by random priming. We found that 12.9% of
sense-AFAS probe pairs have higher expression, by
more than threefold, of the AFAS probe compared to
the sense probe as clearly observed in heat map (Addi-
tional file 1: Figure S4). Also some of AFAS probes
showed such high expression specifically in either nor-
mal or cancer tissues (Figure 4).
Three antisense transcripts detected by our AFAS
probes showed a similar pattern of expression by RT-
PCR (Figure 3). More complete validations of antisense
transcripts detected by our microarray platform were
conducted by RT-PCR, Northern analysis, and in situ
hybridization in our previous work [11]. Our observed
expression patterns of sense genes among normal and
cancer tissues were consistent with those in previously
published work [23].
The reverse transcription step employed to prepare
cDNA for microarray analysis was shown to generate
antisense artifacts [24]. This could be a potential pro-
blem for our random priming approach since we labeled
cDNA generated by reverse transcription. If the synth-
esis of such artifacts was frequent, we would observe a
positive correlation between expression levels of sense
and antisense transcripts. However, we observed no
such correlation in random priming. Therefore, we sug-
gest that the level of artifacts arising from random prim-
ing is minimal. We observed many cases that cannot be
attributed to artifacts where the expression level of the
antisense transcripts is much greater than that of the
corresponding sense transcripts (Figures 5 and 6).
Although some of these antisense transcripts might be
attributed to transcriptional noise [25], which is possibly
enhanced in differentiating cancer cells, we expect that
the certain number of these antisense transcripts are
functional and include non-coding RNAs. The genomic
positions of our detected antisense RNAs are biased
towards the 5’ end of sense genes (Additional file 1: Fig-
ure S6 and [11]). This observation is consistent with
previous reports [5,26] and transcriptions of some of
these antisense RNAs are suggested to be a part of pro-
cesses to maintain chromatin structures for subsequent
gene regulation [27].
There are several biological interpretations for the
function of antisense transcripts detected by AFAS
probes showing altered expression patterns between
normal and cancer tissues. One interpretation is that
they are the result of oncogenesis. For example, during
the process of de-differentiation in oncogenesis, sense or
antisense RNA expression could be altered. Another
interpretation is that the altered expression pattern of
the antisense transcripts might be attributed to pro-
cesses leading to cancer. Some antisense transcripts may
function in the cell by expressional control of sense
genes through epigenetic regulation [21,28]. The
recently discovered non-coding RNA p15AS,w h i c hi s
encoded by the antisense strand of the tumor suppres-
sor gene p15, was shown to regulate the expression of
p15 through heterochromatin formation [21]. This study
revealed that p15AS can suppress the expression of p15
and thus p15 and p15AS have altered expression bal-
ances among normal and leukemia cells; p15 was down-
regulated in leukemia cells, whereas p15AS was up-regu-
lated [21]. Although identification of antisense RNAs
which suppress sense transcripts based solely on
Table 2 Summary of the sense and AFAS transcripts that showed different levels of expression in cancer tissues and in
normal tissues
AFAS probes Corresponding
sense genes
All 2376 (100%) 501 (100%)
AFAS Expression level ≥100 in normal tissue (dT) 213 (9%) 153 (31%)
in cancer tissue (dT) 183 (8%) 138 (28%)
in normal tissue (Random) 931 (39%) 392 (78%)
in cancer tissue (Random) 908 (38%) 388 (77%)
AFAS expression change in cancer tissue Cancer ≥ Normal×2 (Random) 71 (3%) 56 (11%)
Normal ≥ Cancer×2 (Random) 101 (4%) 87 (17%)
Sense-AFAS pair
having altered expression balance
Sense up, AFAS down (Random) 44 (2%) 39 (8%)
Sense down, AFAS up (Random) 5 (0%) 5 (1%)
Sense up (dT), AFAS down (Random) 24 (1%) 17 (3%)
Sense down (dT), AFAS up (Random) 22 (1%) 16 (3%)
Expression levels for “Expression level ≥ 100” and “Expression increased by” were calculated based on median expression levels among patients for each probe.
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Page 11 of 15microarray data is very difficult, we extracted 49 sense-
AFAS probes showing such altered expression balances
(Table 1).
We suspect that Table 1 contains a number of sense-
AFAS gene pairs with an important role in the regula-
tory networks underlying oncogenesis. One such exam-
ple is the sense-AFAS probe pair X07876-03, which
detects expression of wingless-type MMTV integration
site family member 2 (WNT2). WNT2 is known to be
up-regulated in colon cancer and this up-regulation may
be an underlying cause of oncogenesis [29,30]. Another
example is U58334-02 (Figure 6), which detects expres-
sion of tumor protein p53 binding protein 2 (TP53BP2).
TP53BP2 stimulates apoptosis by interacting with the
tumor suppressor p53. Since this process does not con-
tribute to oncogenesis, the altered expression balance
displayed detected by U58334-02 may be the result of
oncogenesis. For cadherin 3 (CDH3), the expression of
which is detected by the sense-AFAS probe pair
X63629-03 (Table 1), a previous study showed that its
expression is increased in breast cancer [31]. Thus, it is
possible that the expressiono fC D H 3i sa l s oi n c r e a s e d
in colon cancer. Clues to the function of CDH3 may be
gained from investigations of the effect of CDH3 up-reg-
ulation on oncogenesis.
Sense-antisense gene pairs that are not directly related
to cancer might also show altered expression balances
in cancer tissues. Besides the 49 sense-AFAS pairs, we
identified 68 sense-antisense transcript pairs among
those identified [10] in colon cancer patients showing
altered expression balances as already described (Figure
1, Additional file 1: Figures S1-2 and Additional file 2:
Table S1).
Cell population heterogeneity should be taken into
account in microarray gene expression analyses since it
might cause the expression level of an antisense tran-
script may to be altered and be masked by the expres-
sion patterns of other cell types. Thus, clear expression
changes might be observed by transcriptional analysis at
a single-cell level. Further investigations involving
knock-down or over-expression experiments would con-
tribute to the identification of antisense transcripts with
an important regulatory role.
For some sense genes, multiple AFAS probes showed
a high level of gene expression, whereas for the other
sense genes, only a single AFAS probe showed a high
level of expression. In the former case, long transcripts
or multiple short transcripts are transcribed from the
antisense strand. Since our AFAS probes are designed
for every 500 bases, the resolution is low. Further
experiments such as Northern blot analysis could be
used to accurately determine the size of these
transcripts.
Finally, our microarray approach, combined with bio-
logical validation, provides an efficient approach to elu-
cidate the regulatory pathways underlying altered
expression of antisense transcripts and might uncover
important roles for these transcripts in oncogenesis. As
a result, this approach has the potential to lead to the
identification of novel biomarkers for cancer.
Conclusion
This study analyzed the expression patterns of well-
known genes and their putative transcriptional units ori-
ginating from the corresponding antisense strand using
our original probes designed specifically to detect anti-
sense strand transcripts. We discovered that many anti-
sense regions are transcribed and that most of these
transcripts are likely to be poly(A)-. Furthermore, we
identified antisense transcripts with altered expression
in cancer tissues as well as those in sense-antisense
transcript pairs displaying altered expression balances in
normal tissue and cancer tissue. Taken together, these
results provide further insight into the regulation of
genes and their antisense transcripts in cancer tissues.
Methods
Preparation of tissue samples
For microarray analysis, we prepared colon cancer tissue
and normal tissue samples that were ~10 cm away from
the cancer tissue, from six patients. Clinical data of the
patients are presented in Additional file 2: Table S6.
Pathological examinations demonstrated that all tumors
included in the study were adenocarcinoma. The
extracted normal tissue was composed mostly of normal
mucosa. The colon cancer and normal tissue samples
were obtained during surgical resection of solitary can-
cerous lesions in the colon. Each tissue sample was
homogenized in liquid nitrogen and total RNA was
extracted using TRIzol Reagent (Gibco BRL, Carlsbad,
California). Transcripts were labeled with fluorescent
dyes by using either oligo-dT or random priming.
The study protocol conformed to the ethical guide-
lines of the Declaration of Helsinki (1975). All patients
provided written informed consent for the analysis of
the biopsy specimens and the hospital ethics committee
approved the study.
Probe design and microarray analysis of well-known
genes and their AFAS
Microarray probes were designed for sense-antisense
transcripts identified by genome mapping of cDNA
sequences. Using the global mean scaling method, the
expression intensities of probes in each array were nor-
malized to those in brain tissue obtained by oligo-dT
priming as previously described [10].
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research was obtained from the Atlas Human Cancer
1.2 Array (Cat. No. 634529, Clontech). For each gene,
we designed probes for every 500 bps to detect expres-
sion from the antisense strand. The optimal position of
each probe was determined by using the tools provided
by Agilent. We excluded well-known genes if the AFAS
probe design failed. Some AFAS probes were designed
on the exon-intron boundaries of the sense strand and
were designated as “truncated” (Additional file 1: Figure
S5). These probes were not included in the analysis
s h o w ni nF i g u r e2 .W ed e s i g n e dat o t a lo f2 3 7 6A F A S
probes covering 501 well-known genes.
Microarray data used in this study have been depos-
ited in GEO and have been assigned series accession
number GSE14397 and GSE14398.
To validate our expression data, we investigated
whether well-known genes known to be regulated in
colon cancer tissues show similar expression profiles in
our system. For each gene, we calculated the median
expression level among patients for normal and cancer
tissues and assessed whether the median expression level
increased or decreased in cancer tissues compared with
normal tissues. For this analysis, we used microarray data
obtained from oligo-dT primed transcripts because the
transcripts of most protein-coding have poly(A) tails. We
compared our gene expression data with previously
reported gene expression analyses of colon cancer tissues
[23]. Of the 245 genes that were previously reported as
showing altered expression in colon cancer, 28 genes
were included in our list of well-known genes. We
showed that 11 of the 14 genes previously shown to be
up-regulated in colon cancer had a higher level of expres-
sion in cancer tissues compared with normal tissues. We
also showed that 12 of the 14 genes previously shown to
be down-regulated in colon cancer had a lower level of
expression in cancer tissues compared with normal tis-
sues. These results show that our data correlate well with
the data of previous studies, thus validating our expres-
sion data. Our microarray data obtained from random
priming of transcripts were similar, although we did not
observe the down-regulation of genes previously shown
to be down-regulated in colon cancer.
We note that although there are correlations among
expression levels detected by multiple AFAS probes for
each well-known gene and also among expression levels
for multiple patients detected by each probe, we
assumed that there were no such correlations in order
to roughly estimate the P-values based on the c
2 tests.
Detection of antisense transcripts by RT-PCR
We performed RT-PCR assays on commercial total RNA:
Human Colon Tumor Total RNA (Clontech), Human
Colon Total RNA (Clontech). We also prepared total
RNA from HUC-Fm (Normal umbilical cord fibroblast,
Cell Bank). For RNA isolation and cDNA synthesis, we
treated total RNA with RQ1 RNase-free DNase (Pro-
mega) to remove contaminating genomic DNA and then
further purified the RNA using Trizol reagent (Invitro-
gen) according to the manufacturer’s recommended pro-
tocols. RNA concentration and the 260/280 nm ratios
were determined with a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies). Total RNA (1 μg)
was reverse transcribed with 50 U of Super ScriptTM III
reverse transcriptase (Invitrogen) using 2.5 ng/μlo f
strand specific primers according to manufacturer’s
instructions. Forward primers were used to transcribe
cDNA from the (-) strand RNA. cDNA samples were
diluted 1:5 in DEPC-treated water prior to real-time PCR.
We performed real-time PCR by using the Thermal
Cycler Dice
® Real Time System (Takara) for quantifica-
tion of transcripts. Reactions were done in 10 μl
volumes containing 200 nM of each primer, 1.0 μl
cDNA, and 5 μlS Y B E R
® Premix EX Taq (Takara). We
used the following primer sequences. For GAPDH-AS
5’- AGTCCACTGGCGTCTTCACC -3 and 5’ - ATGGT
TCACACCCATGACGAAC -3’; for Cxcl12-AS 5’-T C C
CTCACATGTCAGTACCTTCA - 3 and 5’ -G A A T C T
TCATGTCCAGGATTGG- 3; for BRCA2-AS 5’ -G G A
AGTCTGTTTCCACACCTGTC -3 and 5’ - CAGGTGG
AGGTAAAGGCAGTCTA - 3; for TP53BP2-AS 5’ -G C
TCTTCACAATGCTGTGTGTG - 3 and 5’-AAACCGA
TTCCCACAACTGAAG -3. Reactions were run using
the manufacture’s recommended cycling parameters of
9 5° Cf o r1 0sa n d4 0c y c l e so f9 5° Cf o r5sa n d6 0° C
for 30 s. The dissociation curve for each sample was
then analyzed to verify the specificity of each reaction.
The assays were performed in duplicate and the copy
number of each RNA was calculated with Thermal
Cycler Dice
® Real Time System Software (Takara). The
data for each sample were normalized to an internal
standard (GAPDH).
Additional material
Additional file 1: Supplemental figures. Figure S1: Clustering analysis
of the expression ratio of the sense and antisense pair of transcripts.
Figure S2: Changes in expression for sense-antisense gene pairs in
cancer tissues, compared with surrounding normal tissues. Figure S3:
Changes in expression for sense-AFAS gene pairs in cancer tissues,
compared with surrounding normal tissues. Figure S4: Clustering
analysis of the expression ratio of well-known genes (sense transcripts)
and their putative antisense transcripts. Figure S5: Expression intensities
detected by probes designed for the sense gene U69611 and its
corresponding AFAS transcript. Figure S6: Average Expression levels
detected by AFAS probes within every 500 bases with respect to the
both termini of sense transcripts.
Additional file 2: Supplemental tables. Table S1: List of sense-
antisense gene pairs having altered expression balances in cancer tissues
compared to surrounding normal tissues. Table S2: List of gene
categories of sense-antisense transcripts displaying altered expression
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Page 13 of 15balances in normal tissues and cancer tissues. Table S3: Percentages of
probes detecting positive expression according to criteria supplied by
Agilent’s platform. Table S4: List of sense-AFAS pairs detecting altered
expression balances in normal tissues and cancer tissues. Table S5:
Numbers of sense genes belonging to specified functional categories.
Table S6: Clinical data of patients.
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